Minimal Residual Disease Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Global Minimal Residual Disease Market is segmented by test technique (Polymerase Chain Reaction, Fluorescence In Situ Hybridization (FISH), and Next Generation Sequencing (NGS)), target detection (Leukemia, Lymphoma, Solid Tumors, and Others), by end-user (Hospitals, Laboratory centers, and Specialty Clinics) and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The report offers the value (USD million) for the above segments.

Minimal Residual Disease Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Minimal Residual Disease Industry Overview

The minimal residual disease market is highly competitive and consists of several major players. The companies are investing in research and development activities to provide patients with better treatment and detection methods and adopt various business strategies such as collaboration and acquisitions to withhold their positions in the market. Some key players are Adaptive Biotechnologies, Bristol-Myers Squibb Company, Natera, Kite Pharma, and Amgen Inc.

Minimal Residual Disease Market Leaders

  1. Adaptive Biotechnologies

  2. Bristol-Myers Squibb Company

  3. Kite Pharma

  4. Natera

  5. Amgen Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Adaptive Biotechnologies, Bristol-Myers Squibb Company, Kite Pharma, Natera, Amgen Inc.

Global Minimal Residual Disease Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?